{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:47:11Z","timestamp":1786985231901,"version":"build-2736575974"},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006485","name":"National Institute for Genetic Engineering and Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006485","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.biopha.2021.111518","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T08:12:40Z","timestamp":1616055160000},"page":"111518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy"],"prefix":"10.1016","volume":"138","author":[{"given":"Mona Sadat","family":"Mirtaleb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Hossein","family":"Mirtaleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Nosrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalal","family":"Heshmatnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Falak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Zolfaghari Emameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.111518_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102433","article-title":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak","volume":"109","author":"Rothan","year":"2020","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.biopha.2021.111518_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13104-020-05439-x","article-title":"Identification and characterization of a silent mutation in RNA binding domain of N protein coding gene from SARS-CoV-2","volume":"14","author":"Zolfaghari Emameh","year":"2021","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.biopha.2021.111518_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108393","article-title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China","volume":"214","author":"Zhang","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.biopha.2021.111518_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","volume":"55","author":"Devaux","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.biopha.2021.111518_bib5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2021.111518_bib6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.biopha.2021.111518_bib7","first-page":"536","article-title":"Knowledge and attitude towards COVID-19 in Bangladesh: population-level estimation and a comparison","volume":"5","author":"Karim","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2021.111518_bib8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12575-020-00127-3","article-title":"Expansion of single cell transcriptomics data of SARS-CoV infection in human bronchial epithelial cells to COVID-19","volume":"22","author":"Zolfaghari Emameh","year":"2020","journal-title":"Biol. Proced. Online"},{"key":"10.1016\/j.biopha.2021.111518_bib9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ajo.2020.09.027","article-title":"Implications of coronavirus disease 2019 for ophthalmologists","volume":"223","author":"Danesh-Meyer","year":"2021","journal-title":"Am. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.biopha.2021.111518_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.arcmed.2020.09.010","article-title":"Coronavirus Disease (COVID-19): current status and prospects for drug and vaccine development","volume":"52","author":"Ita","year":"2021","journal-title":"Arch. Med. Res."},{"issue":"18","key":"10.1016\/j.biopha.2021.111518_bib11","first-page":"1824","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.biopha.2021.111518_bib12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/joim.13144","article-title":"Cytokine storm syndrome in coronavirus disease 2019: a narrative review","volume":"289","author":"Gao","year":"2021","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.biopha.2021.111518_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12575-020-00124-6","article-title":"Application of system biology to explore the association of neprilysin, angiotensin-converting enzyme 2 (ACE2), and carbonic anhydrase (CA) in pathogenesis of SARS-CoV-2","volume":"22","author":"Zolfaghari Emameh","year":"2020","journal-title":"Biol. Proced. Online"},{"issue":"2","key":"10.1016\/j.biopha.2021.111518_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-045524","article-title":"Impact of COVID-19 on female fertility: a systematic review and meta-analysis protocol","volume":"11","author":"Li","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.biopha.2021.111518_bib15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0065-3527(06)66005-3","article-title":"The molecular biology of coronaviruses","volume":"66","author":"Masters","year":"2006","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.biopha.2021.111518_bib16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.12688\/f1000research.22211.2","article-title":"Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan","volume":"9","author":"Kruse","year":"2020","journal-title":"F1000Research"},{"key":"10.1016\/j.biopha.2021.111518_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12575-020-00121-9","article-title":"Combination of biodata mining and computational modelling in identification and characterization of ORF1ab polyprotein of SARS-CoV-2 isolated from Oronasopharynx of an Iranian Patient","volume":"22","author":"Zolfaghari Emameh","year":"2020","journal-title":"Biol. Proced. Online"},{"key":"10.1016\/j.biopha.2021.111518_bib18","first-page":"1","article-title":"Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2","author":"Jiang","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.biopha.2021.111518_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111352","article-title":"SARS-CoV-2: from the pathogenesis to potential anti-viral treatments","volume":"137","author":"Zarandi","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2021.111518_bib20","first-page":"1","article-title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak\u2013an update on the status","volume":"7","author":"Guo","year":"2020","journal-title":"Mil. Med. Res."},{"issue":"5","key":"10.1016\/j.biopha.2021.111518_bib21","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/bjh.16729","article-title":"Real\u2010world non\u2010interventional long\u2010term post\u2010authorisation safety study of ruxolitinib in myelofibrosis","volume":"191","author":"Barraco","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biopha.2021.111518_bib22","doi-asserted-by":"crossref","DOI":"10.6061\/clinics\/2020\/e2183","article-title":"The interference of COVID-19 in the male reproductive system: important questions and the future of assisted reproduction techniques","volume":"75","author":"de Carvalho","year":"2020","journal-title":"Clinics"},{"issue":"7","key":"10.1016\/j.biopha.2021.111518_bib23","doi-asserted-by":"crossref","first-page":"7760","DOI":"10.1021\/acsnano.0c04006","article-title":"Nanotechnology for COVID-19: therapeutics and vaccine research","volume":"14","author":"Chauhan","year":"2020","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.biopha.2021.111518_bib24","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.biopha.2021.111518_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1050-1738(02)00233-5","article-title":"The role of ACE2 in cardiovascular physiology","volume":"13","author":"Oudit","year":"2003","journal-title":"Trends Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.biopha.2021.111518_bib26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/v12010014","article-title":"Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system?","volume":"12","author":"Desforges","year":"2020","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.biopha.2021.111518_bib27","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1021\/acschemneuro.0c00201","article-title":"Neurological insights of COVID-19 pandemic","volume":"11","author":"Das","year":"2020","journal-title":"ACS Chem. Neurosci."},{"issue":"3","key":"10.1016\/j.biopha.2021.111518_bib28","first-page":"1724","article-title":"Differential expression and immune correlation analysis of COVID-19 receptor ACE2 and TMPRSS2 genes in all normal and tumor tissues","volume":"25","author":"Hu","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2021.111518_bib29","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/molehr\/gaaa030","article-title":"Potential influence of COVID-19\/ACE2 on the female reproductive system","volume":"26","author":"Jing","year":"2020","journal-title":"Mol. Hum. Reprod."},{"key":"10.1016\/j.biopha.2021.111518_bib30","doi-asserted-by":"crossref","DOI":"10.1111\/and.13654","article-title":"Could COVID\u201019 have an impact on male fertility?","volume":"52","author":"Illiano","year":"2020","journal-title":"Andrologia"},{"issue":"2","key":"10.1016\/j.biopha.2021.111518_bib31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3390\/v11020174","article-title":"Global epidemiology of bat coronaviruses","volume":"11","author":"Wong","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2021.111518_bib32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fimmu.2020.00026","article-title":"Novel insights into immune systems of bats","volume":"11","author":"Banerjee","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111518_bib33","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3390\/v11020192","article-title":"Immune system modulation and viral persistence in bats: understanding viral spillover","volume":"11","author":"Subudhi","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2021.111518_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2020.103670","article-title":"Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus","volume":"119","author":"Robson","year":"2020","journal-title":"Comput. Biol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2021.111518_bib35","doi-asserted-by":"crossref","first-page":"vex012","DOI":"10.1093\/ve\/vex012","article-title":"Global patterns in coronavirus diversity","volume":"3","author":"Anthony","year":"2017","journal-title":"Virus Evol."},{"key":"10.1016\/j.biopha.2021.111518_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1758788","article-title":"Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment","author":"Boopathi","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"8","key":"10.1016\/j.biopha.2021.111518_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007236","article-title":"Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2","volume":"14","author":"Song","year":"2018","journal-title":"PLoS Pathog."},{"issue":"11","key":"10.1016\/j.biopha.2021.111518_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049566","article-title":"Ezrin interacts with the SARS coronavirus spike protein and restrains infection at the entry stage","volume":"7","author":"Millet","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.biopha.2021.111518_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01628-17","article-title":"Glycan shield and fusion activation of a deltacoronavirus spike glycoprotein fine-tuned for enteric infections","volume":"92","author":"Xiong","year":"2018","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.biopha.2021.111518_bib40","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues","volume":"181","author":"Ziegler","year":"2020","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.biopha.2021.111518_bib41","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2021.111518_bib42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds","volume":"115","author":"B\u00e1ez-Santos","year":"2015","journal-title":"Antivir. Res."},{"issue":"10223","key":"10.1016\/j.biopha.2021.111518_bib43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.biopha.2021.111518_bib44","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jmb.2005.09.004","article-title":"Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide","volume":"353","author":"Lee","year":"2005","journal-title":"J. Mol. Biol."},{"issue":"8","key":"10.1016\/j.biopha.2021.111518_bib45","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40261-018-0656-y","article-title":"Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review","volume":"38","author":"Plantone","year":"2018","journal-title":"Clin. Drug Investig."},{"issue":"3","key":"10.1016\/j.biopha.2021.111518_bib46","first-page":"489","article-title":"Azithromycin: indications for the future?","volume":"1","author":"Duran","year":"2000","journal-title":"Expert Opin. Drug Deliv."},{"issue":"18","key":"10.1016\/j.biopha.2021.111518_bib47","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1021\/acs.biochem.0c00160","article-title":"Why are lopinavir and ritonavir effective against the newly emerged Coronavirus 2019? Atomistic insights into the inhibitory mechanisms","volume":"59","author":"Nutho","year":"2020","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2021.111518_bib48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.virusres.2016.11.011","article-title":"Alisporivir inhibits MERS-and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model","volume":"228","author":"De Wilde","year":"2017","journal-title":"Virus Res."},{"issue":"17","key":"10.1016\/j.biopha.2021.111518_bib49","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: a review in rheumatoid arthritis","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.biopha.2021.111518_bib50","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/phar.2438","article-title":"Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID\u201019","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.biopha.2021.111518_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2136","article-title":"Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID\u201019) and the rationale for their utilization: a review","volume":"30","author":"Giovane","year":"2020","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.biopha.2021.111518_bib52","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.antiviral.2015.12.006","article-title":"Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses","volume":"126","author":"Westover","year":"2016","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.biopha.2021.111518_bib53","doi-asserted-by":"crossref","DOI":"10.15190\/d.2020.2","article-title":"Emerging therapeutic strategies for COVID-19 patients","volume":"8","author":"Zhu","year":"2020","journal-title":"Discoveries"},{"key":"10.1016\/j.biopha.2021.111518_bib54","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","article-title":"Management of myelofibrosis after ruxolitinib failure","volume":"99","author":"Harrison","year":"2020","journal-title":"Ann. Hematol."},{"issue":"17","key":"10.1016\/j.biopha.2021.111518_bib55","doi-asserted-by":"crossref","first-page":"9218","DOI":"10.1074\/jbc.M116.716100","article-title":"Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome\/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)","volume":"291","author":"Zhou","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2021.111518_bib56","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ijantimicag.2016.07.004","article-title":"Fighting viruses with antibiotics: an overlooked path","volume":"48","author":"Colson","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"6","key":"10.1016\/j.biopha.2021.111518_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2020.04.017","article-title":"Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and treatment?","volume":"82","author":"Patr\u00ec","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"9","key":"10.1016\/j.biopha.2021.111518_bib58","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/14787210.2020.1771181","article-title":"Old and re-purposed drugs for the treatment of COVID-19","volume":"18","author":"Jean","year":"2020","journal-title":"Expert Rev. Anti Infect."},{"key":"10.1016\/j.biopha.2021.111518_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.biopha.2021.111518_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108448","article-title":"COVID-19: immunology and treatment options","volume":"215","author":"Felsenstein","year":"2020","journal-title":"Clin. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2021.111518_bib61","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/NOR.0000000000000595","article-title":"Corticosteroids","volume":"38","author":"Kapugi","year":"2019","journal-title":"Orthop. Nurs."},{"issue":"4","key":"10.1016\/j.biopha.2021.111518_bib62","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13437","article-title":"Doxycycline, a widely used antibiotic in dermatology with a possible anti\u2010inflammatory action against IL\u20106 in COVID\u201019 outbreak","volume":"33","author":"Conforti","year":"2020","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.biopha.2021.111518_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2020.e00864","article-title":"Doxycycline as a potential partner of COVID-19 therapies","volume":"21","author":"Malek","year":"2020","journal-title":"IDCases"},{"issue":"11","key":"10.1016\/j.biopha.2021.111518_bib64","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today\u2019s diseases","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect. Dis."},{"issue":"15","key":"10.1016\/j.biopha.2021.111518_bib65","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2021.111518_bib66","first-page":"1","article-title":"Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story","author":"Gasmi","year":"2021","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"3","key":"10.1016\/j.biopha.2021.111518_bib67","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"issue":"10223","key":"10.1016\/j.biopha.2021.111518_bib68","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.biopha.2021.111518_bib69","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijantimicag.2007.05.015","article-title":"Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century","volume":"30","author":"Rolain","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"6","key":"10.1016\/j.biopha.2021.111518_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105980","article-title":"Chloroquine as a prophylactic agent against COVID-19?","volume":"55","author":"Gendrot","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"9","key":"10.1016\/j.biopha.2021.111518_bib71","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cmi.2020.05.006","article-title":"Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19","volume":"26","author":"Gevers","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.biopha.2021.111518_bib72","article-title":"Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature","author":"De Luca","year":"2020","journal-title":"Am. J. Otolaryngol."},{"key":"10.1016\/j.biopha.2021.111518_bib73","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jcrc.2020.03.005","article-title":"A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","volume":"57","author":"Cortegiani","year":"2020","journal-title":"J. Crit. Care"},{"key":"10.1016\/j.biopha.2021.111518_bib74","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of covId-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci. Trends"},{"key":"10.1016\/j.biopha.2021.111518_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104762","article-title":"Of chloroquine and COVID-19","volume":"177","author":"Touret","year":"2020","journal-title":"Antivir. Res."},{"issue":"9","key":"10.1016\/j.biopha.2021.111518_bib76","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jamacardio.2020.1834","article-title":"Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)","volume":"5","author":"Mercuro","year":"2020","journal-title":"JAMA Cardiol."},{"issue":"4","key":"10.1016\/j.biopha.2021.111518_bib77","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"11","key":"10.1016\/j.biopha.2021.111518_bib78","doi-asserted-by":"crossref","first-page":"ofaa500","DOI":"10.1093\/ofid\/ofaa500","article-title":"Safety of hydroxychloroquine among outpatient clinical trial participants for COVID-19","volume":"7","author":"Lofgren","year":"2020","journal-title":"OFID"},{"key":"10.1016\/j.biopha.2021.111518_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmni.2020.100747","article-title":"Hydroxychloroquine is protective to the heart, not harmful: a systematic review","volume":"37","author":"Prodromos","year":"2020","journal-title":"New Microbes New Infect."},{"issue":"1","key":"10.1016\/j.biopha.2021.111518_bib80","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/jac\/dkaa403","article-title":"Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis","volume":"76","author":"Kashour","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.biopha.2021.111518_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173928","article-title":"Chloroquine: autophagy inhibitor, antimalarial, bitter taste receptor agonist in fight against COVID-19, a reality check?","volume":"897","author":"Sharma","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"10256","key":"10.1016\/j.biopha.2021.111518_bib82","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0140-6736(20)31863-8","article-title":"Azithromycin for severe COVID-19","volume":"396","author":"Oldenburg","year":"2020","journal-title":"Lancet"},{"issue":"1\u20132","key":"10.1016\/j.biopha.2021.111518_bib83","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejphar.2006.03.074","article-title":"Anti-inflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice","volume":"539","author":"Iveti\u0107 Tkal\u010devi\u0107","year":"2006","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2021.111518_bib84","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.58","article-title":"Azithromycin inhibits nuclear factor\u2010\u03baB activation during lung inflammation: an in vivo imaging study","volume":"2","author":"Stellari","year":"2014","journal-title":"Pharmacol. Res. Perspect."},{"issue":"8","key":"10.1016\/j.biopha.2021.111518_bib85","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40264-020-00976-7","article-title":"Azithromycin in COVID-19 patients: pharmacological mechanism, clinical evidence and prescribing guidelines","volume":"43","author":"Sultana","year":"2020","journal-title":"Drug Saf."},{"issue":"2","key":"10.1016\/j.biopha.2021.111518_bib86","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/cpt.1857","article-title":"Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID\u201019.","volume":"108","author":"Damle","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2021.111518_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"4","key":"10.1016\/j.biopha.2021.111518_bib88","first-page":"215","article-title":"New antiretroviral therapies for pediatric HIV infection","volume":"10","author":"Morris","year":"2005","journal-title":"J. Pediatr. Pharmacol. Ther."},{"issue":"19","key":"10.1016\/j.biopha.2021.111518_bib89","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMe2005477","article-title":"Covid-19 \u2014 the search for effective therapy","volume":"382","author":"Baden","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2021.111518_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.biopha.2021.111518_bib91","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2165\/00003495-200060060-00009","article-title":"Lopinavir","volume":"60","author":"Hurst","year":"2000","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.biopha.2021.111518_bib92","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture","volume":"58","author":"De Wilde","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.biopha.2021.111518_bib93","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"issue":"15","key":"10.1016\/j.biopha.2021.111518_bib94","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1097\/00002030-200210180-00015","article-title":"Clinical use of lopinavir\/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics","volume":"16","author":"Boffito","year":"2002","journal-title":"Aids"},{"issue":"1","key":"10.1016\/j.biopha.2021.111518_bib95","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcv.2004.03.003","article-title":"In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds","volume":"31","author":"Chen","year":"2004","journal-title":"J. Clin. Virol."},{"issue":"6","key":"10.1016\/j.biopha.2021.111518_bib96","first-page":"3390","article-title":"Clinical efficacy of lopinavir\/ritonavir in the treatment of Coronavirus disease 2019","volume":"24","author":"Ye","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2021.111518_bib97","first-page":"1","article-title":"Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy","author":"Hong","year":"2020","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"10.1016\/j.biopha.2021.111518_bib98","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/jmv.25798","article-title":"Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning COVID\u201019","volume":"92","author":"Khalili","year":"2020","journal-title":"J. Med. Virol."},{"issue":"9","key":"10.1016\/j.biopha.2021.111518_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030343","article-title":"SARS: systematic review of treatment effects","volume":"3","author":"Stockman","year":"2006","journal-title":"PLoS Med."},{"issue":"3","key":"10.1016\/j.biopha.2021.111518_bib100","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.1977","article-title":"Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta\u2010analysis","volume":"28","author":"Morra","year":"2018","journal-title":"Rev. Med. Virol."},{"issue":"9","key":"10.1016\/j.biopha.2021.111518_bib101","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1093\/cid\/ciz544","article-title":"Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: a multicenter observational study","volume":"70","author":"Arabi","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"10238","key":"10.1016\/j.biopha.2021.111518_bib102","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.biopha.2021.111518_bib103","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/CIRCULATIONAHA.120.046702","article-title":"Deep vein thrombosis in hospitalized patients with COVID-19 in Wuhan, China: prevalence, risk factors, and outcome","volume":"142","author":"Zhang","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.biopha.2021.111518_bib104","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.virol.2005.07.015","article-title":"Coordinate induction of IFN-\u03b1 and-\u03b3 by SARS-CoV also in the absence of virus replication","volume":"341","author":"Castilletti","year":"2005","journal-title":"Virology"},{"issue":"11","key":"10.1016\/j.biopha.2021.111518_bib105","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.molimm.2005.11.005","article-title":"The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization","volume":"43","author":"Shi","year":"2006","journal-title":"Mol. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2021.111518_bib106","doi-asserted-by":"crossref","first-page":"7977","DOI":"10.4049\/jimmunol.174.12.7977","article-title":"Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection","volume":"174","author":"Tseng","year":"2005","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.biopha.2021.111518_bib107","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID\u201019: a single center experience","volume":"92","author":"Luo","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.biopha.2021.111518_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104380","article-title":"Supportive treatment with tocilizumab for COVID-19: a systematic review","volume":"127","author":"Alzghari","year":"2020","journal-title":"J. Clin. Virol."},{"issue":"4","key":"10.1016\/j.biopha.2021.111518_bib109","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"4","key":"10.1016\/j.biopha.2021.111518_bib110","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1161\/01.RES.0000205761.22353.5f","article-title":"Angiotensin-converting enzyme II in the heart and the kidney","volume":"98","author":"Danilczyk","year":"2006","journal-title":"Circ. Res."},{"key":"10.1016\/j.biopha.2021.111518_bib111","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.antiviral.2018.05.001","article-title":"Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment","volume":"155","author":"Pu","year":"2018","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.biopha.2021.111518_bib112","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.str.2015.12.015","article-title":"Family-wide structural analysis of human numb-associated protein kinases","volume":"24","author":"Sorrell","year":"2016","journal-title":"Structure"},{"issue":"6","key":"10.1016\/j.biopha.2021.111518_bib113","first-page":"394","article-title":"Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis","volume":"13","author":"Mesa","year":"2010","journal-title":"IDrugs"},{"issue":"10","key":"10.1016\/j.biopha.2021.111518_bib114","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.4049\/jimmunol.1601896","article-title":"Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection","volume":"198","author":"Channappanavar","year":"2017","journal-title":"J. Immunol."},{"issue":"10229","key":"10.1016\/j.biopha.2021.111518_bib115","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.biopha.2021.111518_bib116","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/psb.1586","article-title":"Baricitinib: a new oral treatment for rheumatoid arthritis","volume":"28","author":"Chaplin","year":"2017","journal-title":"Prescriber"},{"key":"10.1016\/j.biopha.2021.111518_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105967","article-title":"Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19","volume":"55","author":"Praveen","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.biopha.2021.111518_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2020.104554","article-title":"Immunopathological similarities between COVID-19 and influenza: investigating the consequences of Co-infection","volume":"152","author":"Khorramdelazad","year":"2021","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.biopha.2021.111518_bib119","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo [2, 1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of ebola and emerging viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.biopha.2021.111518_bib120","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2020.35.e221","article-title":"Uncertainty about the efficacy of Remdesivir on COVID-19","volume":"35","author":"Yoo","year":"2020","journal-title":"J. Korean Med. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2021.111518_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105933","article-title":"Arguments in favour of remdesivir for treating SARS-CoV-2 infections","volume":"55","author":"Ko","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"4","key":"10.1016\/j.biopha.2021.111518_bib122","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/v11040326","article-title":"Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir","volume":"11","author":"Tchesnokov","year":"2019","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.biopha.2021.111518_bib123","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.dsx.2020.05.018","article-title":"Remdesivir in COVID-19: a critical review of pharmacology, pre-clinical and clinical studies","volume":"14","author":"Singh","year":"2020","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"issue":"18","key":"10.1016\/j.biopha.2021.111518_bib124","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2021.111518_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101615","article-title":"Remdesivir as a possible therapeutic option for the COVID-19","volume":"34","author":"Al-Tawfiq","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.biopha.2021.111518_bib126","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus\u00a0(2019 nCoV) in vitro","volume":"30","author":"Wang","year":"2019","journal-title":"Cell Res."},{"issue":"10043","key":"10.1016\/j.biopha.2021.111518_bib127","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(16)30386-5","article-title":"Late Ebola virus relapse causing meningoencephalitis: a case report","volume":"388","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2021.111518_bib128","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-020-01378-w","article-title":"Remdesivir: first approval","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"issue":"24","key":"10.1016\/j.biopha.2021.111518_bib129","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.biopha.2021.111518_bib130","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.biopha.2021.111518_bib131","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2021.111518_bib132","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001967","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.biopha.2021.111518_bib133","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"Oestereich","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.biopha.2021.111518_bib134","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2014.01.012","article-title":"Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model","volume":"104","author":"Smither","year":"2014","journal-title":"Antivir. Res."},{"issue":"10","key":"10.1016\/j.biopha.2021.111518_bib135","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering"},{"issue":"1","key":"10.1016\/j.biopha.2021.111518_bib136","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jinf.2020.03.060","article-title":"Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19","volume":"81","author":"Zhu","year":"2020","journal-title":"J. Infect."},{"issue":"10","key":"10.1016\/j.biopha.2021.111518_bib137","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2174\/092986708784049658","article-title":"Arbidol: a broad-spectrum antiviral compound that blocks viral fusion","volume":"15","author":"Boriskin","year":"2008","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2021.111518_bib138","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jinf.2020.03.002","article-title":"Arbidol combined with LPV\/r versus LPV\/r alone against Corona Virus Disease 2019: a retrospective cohort study","volume":"81","author":"Deng","year":"2020","journal-title":"J. Infect."},{"issue":"10.1016","key":"10.1016\/j.biopha.2021.111518_bib139","article-title":"Teicoplanin: an alternative drug for the treatment of COVID-19?","volume":"55","author":"Baron","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"6","key":"10.1016\/j.biopha.2021.111518_bib140","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4269\/ajtmh.20-0271","article-title":"Ivermectin and COVID-19: keeping rigor in times of urgency","volume":"102","author":"Chaccour","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.biopha.2021.111518_bib141","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3329\/jbcps.v38i0.47512","article-title":"A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline","volume":"38","author":"Alam","year":"2020","journal-title":"J. Bangladesh Coll. Phys. Surg."},{"key":"10.1016\/j.biopha.2021.111518_bib142","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3329\/jbcps.v38i0.47514","article-title":"Comparison of viral clearance between ivermectin with doxycycline and hydroxychloroquine with azithromycin in COVID-19 patients","author":"Rahman","year":"2020","journal-title":"J. Bangladesh Coll. Physicians Surg."},{"key":"10.1016\/j.biopha.2021.111518_bib143","doi-asserted-by":"crossref","DOI":"10.1177\/1753466620951053","article-title":"Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease","volume":"14","author":"Yates","year":"2020","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.biopha.2021.111518_bib144","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3332\/ecancer.2020.1023","article-title":"COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?","volume":"14","author":"Russell","year":"2020","journal-title":"Ecancermedicalscience"},{"issue":"4","key":"10.1016\/j.biopha.2021.111518_bib145","article-title":"Glucocorticoid application in the treatment of coronavirus disease 2019 (COVID-19): the pros and cons","volume":"41","author":"Chen","year":"2020","journal-title":"Med. J. Wuhan Univ."},{"key":"10.1016\/j.biopha.2021.111518_bib146","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1080\/21645515.2020.1825896","article-title":"Recent advances in vaccine and immunotherapy for COVID-19","volume":"16","author":"Rabaan","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"issue":"4","key":"10.1016\/j.biopha.2021.111518_bib147","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"16","key":"10.1016\/j.biopha.2021.111518_bib148","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.2020.4940","article-title":"Convalescent plasma to treat COVID-19: possibilities and challenges","volume":"323","author":"Roback","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.biopha.2021.111518_bib149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1203\/01.PDR.0000129184.87042.FC","article-title":"Sars: the first pandemic of the 21 st century","volume":"56","author":"Cherry","year":"2004","journal-title":"Pediatr. Res."},{"issue":"6","key":"10.1016\/j.biopha.2021.111518_bib150","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/MOH.0000000000000191","article-title":"The use of convalescent plasma to treat emerging infectious diseases: focus on Ebola virus disease","volume":"22","author":"Winkler","year":"2015","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.biopha.2021.111518_bib151","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1080\/21645515.2020.1793712","article-title":"Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19","volume":"16","author":"Al-Tawfiq","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"issue":"1","key":"10.1016\/j.biopha.2021.111518_bib152","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1511812","article-title":"Evaluation of convalescent plasma for Ebola virus disease in Guinea","volume":"374","author":"Van Griensven","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.biopha.2021.111518_bib153","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.biopha.2021.111518_bib154","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.biopha.2021.111518_bib155","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41582-020-0385-8","article-title":"Neurological immunotherapy in the era of COVID-19\u2014looking for consensus in the literature","volume":"16","author":"Korsukewitz","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.biopha.2021.111518_bib156","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/jcp.30076","article-title":"Immunobiology and immunotherapy of COVID\u201019: a clinically updated overview","volume":"236","author":"Esmaeilzadeh","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.biopha.2021.111518_bib157","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012465","article-title":"COVID\u201019: lambda interferon against viral load and hyperinflammation","volume":"12","author":"Andreakos","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.biopha.2021.111518_bib158","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cytogfr.2020.05.002","article-title":"COVID-19: pathogenesis, cytokine storm and therapeutic potential of interferons","volume":"53","author":"Nile","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.biopha.2021.111518_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104791","article-title":"Type 1 interferons as a potential treatment against COVID-19","volume":"178","author":"Sallard","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.biopha.2021.111518_bib160","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3389\/fimmu.2020.01061","article-title":"Interferon-\u03b12b Treatment for COVID-19","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2021.111518_bib161","first-page":"1","article-title":"Cell-based therapy for severe COVID-19 patients: clinical trials and cost-utility","author":"Golchin","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.biopha.2021.111518_bib162","first-page":"1","article-title":"Mesenchymal stem cell therapy for COVID-19: present or future","author":"Golchin","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"issue":"31","key":"10.1016\/j.biopha.2021.111518_bib163","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021429","article-title":"Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: a case report","volume":"99","author":"Liang","year":"2020","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.biopha.2021.111518_bib164","doi-asserted-by":"crossref","first-page":"216","DOI":"10.14336\/AD.2020.0228","article-title":"Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia","volume":"11","author":"Leng","year":"2020","journal-title":"Aging Dis."},{"issue":"3","key":"10.1016\/j.biopha.2021.111518_bib165","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.3390\/ijms15034142","article-title":"Exosomes derived from mesenchymal stem cells","volume":"15","author":"Yu","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2021.111518_bib166","first-page":"1","article-title":"Mesenchymal stem cell derived exosomes: a nano platform for therapeutics and drug delivery in combating COVID-19","author":"Gupta","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.biopha.2021.111518_bib167","first-page":"1","article-title":"Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective","author":"Gupta","year":"2020","journal-title":"Hum. Cell"},{"issue":"1","key":"10.1016\/j.biopha.2021.111518_bib168","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/35095564","article-title":"Natural killer cells, viruses and cancer","volume":"1","author":"Cerwenka","year":"2001","journal-title":"Nat. Rev. Immunol."},{"issue":"s1","key":"10.1016\/j.biopha.2021.111518_bib169","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.biopha.2021.111518_bib170","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.4049\/jimmunol.178.5.2688","article-title":"NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection","volume":"178","author":"Draghi","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2021.111518_bib171","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fimmu.2019.00022","article-title":"Nanoparticle-based vaccines against respiratory viruses","volume":"10","author":"Al-Halifa","year":"2019","journal-title":"Front. Immunol."},{"issue":"24","key":"10.1016\/j.biopha.2021.111518_bib172","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.3390\/molecules25245952","article-title":"Nano-biomimetic drug delivery vehicles: potential approaches for COVID-19 treatment","volume":"25","author":"Witika","year":"2020","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.biopha.2021.111518_bib173","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1021\/acsnano.0c02857","article-title":"Computational design of ACE2-based peptide inhibitors of SARS-CoV-2","volume":"14","author":"Han","year":"2020","journal-title":"ACS Nano"},{"issue":"8","key":"10.1016\/j.biopha.2021.111518_bib174","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41565-020-0752-z","article-title":"Dexamethasone nanomedicines for COVID-19","volume":"15","author":"Lammers","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.biopha.2021.111518_bib175","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.3390\/molecules25092193","article-title":"Therapeutic nanoparticles and their targeted delivery applications","volume":"25","author":"Yetisgin","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2021.111518_bib176","first-page":"1","article-title":"Engineered nanomaterials as fighters against SARS-CoV-2: the way to control and treat pandemics","author":"Abd Elkodous","year":"2020","journal-title":"Environ. Sci. Pollut. Res."},{"key":"10.1016\/j.biopha.2021.111518_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118663","article-title":"Carrier-free nanodrug: a novel strategy of cancer diagnosis and synergistic therapy","volume":"570","author":"Yang","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"10","key":"10.1016\/j.biopha.2021.111518_bib178","doi-asserted-by":"crossref","first-page":"12522","DOI":"10.1021\/acsnano.0c07197","article-title":"COVID-19 vaccine frontrunners and their nanotechnology design","volume":"14","author":"Chung","year":"2020","journal-title":"ACS Nano"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221003036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221003036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:28:41Z","timestamp":1760099321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221003036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":178,"alternative-id":["S0753332221003036"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111518","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111518","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"111518"}}